The company is speaking with advisers to help field interest, said the people, who asked not to be identified because the information is private. Jazz Pharma is also studying possibilities that might include a breakup or divestment of parts of the business, the people said.
Separating its cannabinoid business from its oncology operations is one of the possibilities, the people said. Jazz Pharma agreed in 2021 to
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.